How Will Skyrizi and Rinvoq Sales Aid AbbVie's Upcoming Q2 Results?

AbbVie is poised to report strong Q2 results driven by its immunology drugs Skyrizi and Rinvoq, with combined sales projected at $6 billion, enabling the company to navigate Humira's loss of exclusivity and return to overall growth by 2025. These drugs have demonstrated robust uptake across key indications like IBD and recent expansions such as GCA, while AbbVie also diversifies into oncology and neuroscience. Despite a competitive immunology market and a valuation trading above its five-year average, the successful pipeline execution underpins the positive outlook.

Analysis

AbbVie's strategic execution in navigating the loss of exclusivity for Humira appears effective, with its upcoming Q2 results poised to be driven by its successor immunology drugs, Skyrizi and Rinvoq. The market is anticipating combined sales of $6 billion from these two assets for the quarter, with model estimates pegging Skyrizi at $4 billion and Rinvoq at $2 billion. This strong commercial uptake, fueled by expansions into new indications like giant cell arteritis (GCA) and continued penetration in the inflammatory bowel disease (IBD) market, is fundamental to the company's projection of returning to overall growth in 2025. While the company is also building out its oncology and neuroscience franchises, the immunology portfolio remains the core focus. The stock's valuation reflects this optimism, as its forward P/E of 14.21x trades above its five-year mean of 12.48x, suggesting that positive performance is largely priced in. The competitive landscape remains intense, with formidable rivals like Johnson & Johnson's Tremfya and Eli Lilly's Omvoh vying for market share, making sustained execution critical.

Key Decisions for Investors

• Investors should focus on the upcoming July 31 earnings report, specifically whether Skyrizi and Rinvoq sales meet the $6 billion combined target, as this is the primary validation for the company's 2025 growth thesis.
• Given the stock has outperformed the industry year-to-date and trades above its historical valuation average, consider whether the current price adequately reflects the successful post-Humira transition or if a significant earnings beat is required for further upside.
• Monitor the competitive dynamics and market share data for rival immunology drugs from Johnson & Johnson and Eli Lilly, as their commercial success represents the most direct risk to AbbVie's long-term growth in this critical therapeutic area.